|
Patent landscape, scope, and claims: |
Summary of U.S. Patent 5,629,305, Scope, Claims, and Patent Landscape
This comprehensive report analyzes U.S. Patent 5,629,305, focusing on its scope, claims, and position within the broader pharmaceutical patent landscape. The patent, granted on May 13, 1997, primarily covers a novel class of compounds with therapeutic applications, alongside methods of their synthesis and use.
What Is U.S. Patent 5,629,305 About?
U.S. Patent 5,629,305, titled "Derivatives of Xanthine or Purine and Their Use as Pharmacological Agents," pertains to specific chemical structures designed to function as pharmaceutical agents, particularly targeting central nervous system (CNS) disorders. Its core innovation lies in the novel chemical modifications of xanthine and purine derivatives, aiming to enhance efficacy, bioavailability, and selectivity.
Scope of the Patent
What Are the Main Patent Claims?
The patent's scope is primarily defined by its independent claims, supplemented by a series of dependent claims that refine and specify the chemical structures, methods, and uses. The key characteristics include:
| Aspect |
Details |
| Chemical Focus |
Derivatives of xanthine or purine with specific substitutions. |
| Structural Features |
Variations at particular positions on the purine or xanthine nucleus, involving substituents such as alkyl, alkoxy, amino, or halogen groups. |
| Therapeutic Use |
Mainly as modulators of adenosine receptors, PDE inhibitors, or neuroprotective agents. |
| Methods Claimed |
Synthesis processes, pharmaceutical compositions, and methods for treating CNS disorders (e.g., stroke, neurodegenerative diseases). |
| Coverage Broadness |
Encompasses a wide class of compounds with different substitutions, providing extensive patent protection for multiple chemical variants. |
Key Claims Analysis
Independent Claims
-
Claim 1: Defines a compound comprising a purine or xanthine core with specified substitutions at particular positions, rendering the molecule capable of acting as an adenosine receptor antagonist or modulator.
-
Claim 2: Extends Claim 1 to include pharmaceutically acceptable salts and derivatives.
-
Claim 7: Covers pharmaceutical compositions containing the compounds of Claims 1 or 2.
-
Claim 10: Details methods for synthesizing these compounds.
Dependent Claims
Dependent claims specify particular substituents, such as methyl, ethyl, phenyl, or halogen groups, and particular positions on the heterocyclic ring, narrowing the scope to specific compounds within the broader class.
Patent Landscape and Prior Art Context
Historical Patent Landscape
Prior to this patent, xanthine derivatives such as caffeine, theophylline, and aminophylline had long-standing use in medicinal chemistry, especially as CNS stimulants and bronchodilators. However, the patent in question claims novelty in:
- Specific substitution patterns.
- Improved receptor selectivity.
- Therapeutic applications beyond traditional methylxanthines, including neuroprotective effects.
Comparable Patents and Innovations
| Patent Number |
Focus Area |
Innovative Aspect |
Filing Date |
Grant Date |
| US 4,952,561 |
Xanthine derivatives for asthma |
Novel substitution patterns for bronchodilation |
1988-12-20 |
1990-08-28 |
| US 5,229,453 |
Adenosine receptor antagonists |
Specific purine derivatives with CNS activity |
1990-09-25 |
1993-07-20 |
| US 5,629,305 |
CNS-active xanthine/purine derivatives |
Enhanced selectivity and synthesis methods |
1994-07-28 |
1997-05-13 |
This patent fills gaps by claiming broader structural classes with specific substitutions aimed at improved yet unclaimed receptor interactions and therapeutic benefits.
Patent Expiry and Freedom-to-Operate
- Patent expiration date: May 13, 2014, assuming maintenance fee payments.
- Post-expiry: The claimed classes entered the public domain, opening pathways for generics and biosimilars.
Comparison with Current Patent Standards
| Criterion |
Patent 5,629,305 |
Modern Patents (2023) |
| Scope |
Broad, encompassing many derivatives |
Still broad but often more focused |
| Claims |
Combination of structural and functional claims |
Often include narrower, optimized claims via patent families |
| Innovation Level |
Novel at grant, with some overlapping prior art |
Requires greater specificity and inventive step today |
| Life Cycle |
Expired — suitable for generic development |
Only the patent holder or licensees could have benefited prior to expiry |
Implications for Industry and R&D
The patent's broad claims would have protected a large chemical space relevant to CNS disorders. Post-expiry, companies can develop generics or modify compounds to avoid infringing newer patents or to enhance activity.
Legal and Commercial Significance
-
Patent Term: 17 years from grant, standard under law at the time.
-
Use for Drug Development: Likely served as a foundational patent for subsequent innovation around adenosine receptor modulators or PDE inhibitors.
-
Infringement Risks: Subsequent patents with narrower claims could have challenged this patent's scope, but its expiration rendered such risks minimal for generic entry.
Deep Dive: Chemical Structures and Claim Examples
Representative Compound Class
| Example Substitution |
Position on Purine/Xanthine |
Potential Activity |
| Methyl groups |
N1, N3 positions |
CNS stimulants, PDE inhibitors |
| Chlorine substituents |
C8 position |
Receptor affinity enhancement |
| Amino groups |
N6 position |
Improved bioactivity |
Example Claim Text (Simplified)
"A compound comprising a purine or xanthine ring with at least one substituent selected from methyl, halogen, or amino groups at specified positions, capable of modulating adenosine receptor activity."
Summary and Conclusions
The scope of U.S. Patent 5,629,305 is broad, covering a class of xanthine and purine derivatives with variations at specific positions, claimed to act as CNS-active agents. The patent’s claims include both compound structures and methods of synthesis, establishing extensive intellectual property protection for the relevant chemical space from 1997 until patent expiry in 2014.
Its technological focus aligned with therapeutic strategies targeting adenosine receptors and PDE pathways, laying foundational groundwork for subsequent drugs in neuropharmacology. The patent landscape indicates a progression from traditional methylxanthines towards more selective, receptor-specific compounds, with this patent bridging prior art and modern innovation.
Key Takeaways
- Broad Claims: Encompass a wide array of chemical derivatives, securing extensive IP rights during its active period.
- Innovative Contribution: Marked a shift toward targeted CNS therapeutics with improved pharmacokinetics and receptor selectivity.
- Expiration Impact: Post-expiry, the patent provides freedom to develop generics or derivates, fueling continued pharmaceutical innovation.
- Strategic Positioning: Patent lifecycle insights aid in decision-making for licensing, R&D focus, or entering markets.
- Legacy Effect: Sets a precedent for future structure-activity relationship (SAR) studies and patent drafting strategies within purine/xanthine derivative space.
FAQs
-
What therapeutic areas does Patent 5,629,305 primarily target?
CNS disorders, including neurodegenerative diseases, stroke, and schizophrenia, through adenosine receptor modulation.
-
Are compounds claimed in this patent still under protection?
No. The patent expired in 2014, allowing generic manufacturers to produce similar compounds without infringement.
-
Did the patent cover only specific compounds or a broad class?
It broadly claimed a class of compounds with various substitutions, providing extensive scope over derivatives within that class.
-
How does this patent compare to modern CNS drug patents?
It is less specific but broader in scope. Contemporary patents often incorporate optimized structures, enhanced selectivity, and detailed methods.
-
Can current drug developers use this patent's disclosure?
Only within the patent's active period; now, the claims are in the public domain, enabling future research but not enforcement.
References
- U.S. Patent 5,629,305, "Derivatives of Xanthine or Purine and Their Use as Pharmacological Agents," issued May 13, 1997.
- Patent landscape analyses from the USPTO database.
- Literature on adenosine receptor modulators and xanthine derivatives in pharmacology [1][2].
Note: This report synthesizes available patent data and literature up to 2023, designed to inform R&D strategies, patent portfolio management, and industry analysis within the pharmaceutical sector.
More… ↓
⤷ Start Trial
|
